NYSE:DGX - Quest Diagnostics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $107.97 +0.44 (+0.41 %) (As of 09/20/2018 03:50 PM ET)Previous Close$108.09Today's Range$107.48 - $108.2052-Week Range$90.10 - $116.49Volume23,292 shsAverage Volume730,628 shsMarket Capitalization$14.65 billionP/E Ratio20.00Dividend Yield1.87%Beta0.74 Company ProfileDiscussionAnalyst RatingsChartDividend HistoryEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. Receive DGX News and Ratings via Email Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Medical laboratories Sub-IndustryHealth Care Services SectorMedical SymbolNYSE:DGX CUSIP74834L10 Webwww.questdiagnostics.com Phone973-520-2700 Debt Debt-to-Equity Ratio0.65 Current Ratio1.12 Quick Ratio1.05 Price-To-Earnings Trailing P/E Ratio20.00 Forward P/E Ratio16.41 P/E Growth2.04 Sales & Book Value Annual Sales$7.71 billion Price / Sales1.91 Cash Flow$7.4411 per share Price / Cash14.51 Book Value$36.35 per share Price / Book2.97 Profitability EPS (Most Recent Fiscal Year)$5.40 Net Income$772 million Net Margins10.56% Return on Equity15.45% Return on Assets7.33% Miscellaneous Employees45,000 Outstanding Shares136,670,000Market Cap$14.65 billion Quest Diagnostics (NYSE:DGX) Frequently Asked Questions What is Quest Diagnostics' stock symbol? Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX." How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics? Quest Diagnostics announced a quarterly dividend on Friday, August 17th. Stockholders of record on Friday, October 5th will be paid a dividend of $0.50 per share on Monday, October 22nd. This represents a $2.00 annualized dividend and a dividend yield of 1.85%. The ex-dividend date of this dividend is Thursday, October 4th. View Quest Diagnostics' Dividend History. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics announced that its Board of Directors has authorized a stock repurchase plan on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 7.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's leadership believes its shares are undervalued. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Inc (NYSE:DGX) posted its quarterly earnings data on Tuesday, July, 24th. The medical research company reported $1.75 EPS for the quarter, missing the Zacks' consensus estimate of $1.76 by $0.01. The medical research company had revenue of $1.92 billion for the quarter, compared to the consensus estimate of $1.95 billion. Quest Diagnostics had a net margin of 10.56% and a return on equity of 15.45%. The business's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.55 earnings per share. View Quest Diagnostics' Earnings History. When is Quest Diagnostics' next earnings date? Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, October, 18th 2018. View Earnings Estimates for Quest Diagnostics. What guidance has Quest Diagnostics issued on next quarter's earnings? Quest Diagnostics updated its FY18 earnings guidance on Tuesday, July, 24th. The company provided earnings per share (EPS) guidance of $6.53-6.57 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.61. The company issued revenue guidance of $7.70-7.74 billion, compared to the consensus revenue estimate of $7.72 billion. What price target have analysts set for DGX? 20 analysts have issued 1 year price objectives for Quest Diagnostics' shares. Their forecasts range from $86.00 to $130.00. On average, they expect Quest Diagnostics' stock price to reach $109.9375 in the next year. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for Quest Diagnostics. What is the consensus analysts' recommendation for Quest Diagnostics? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 10 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quest Diagnostics. Who are some of Quest Diagnostics' key competitors? Some companies that are related to Quest Diagnostics include Laboratory Corp. of America (LH), ELEKTA AB/ADR (EKTAY), Foundation Medicine (FMI), Genomic Health (GHDX), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD) and Fulgent Genetics (FLGT). Who are Quest Diagnostics' key executives? Quest Diagnostics' management team includes the folowing people: Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 61)Mr. Mark J. Guinan, Exec. VP & CFO (Age 56)Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 55)Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 55)Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 43) Has Quest Diagnostics been receiving favorable news coverage? Headlines about DGX stock have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Quest Diagnostics earned a daily sentiment score of 0.18 on Accern's scale. They also gave news articles about the medical research company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Quest Diagnostics. Who are Quest Diagnostics' major shareholders? Quest Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.91%), Macquarie Group Ltd. (4.68%), American Century Companies Inc. (2.17%), Victory Capital Management Inc. (1.88%), Northern Trust Corp (1.50%) and Dimensional Fund Advisors LP (1.46%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jenne K Britell, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics. Which major investors are selling Quest Diagnostics stock? DGX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Macquarie Group Ltd., Morgan Stanley, Capital Fund Management S.A., Wells Fargo & Company MN, Rockefeller Capital Management L.P. and Polaris Capital Management LLC. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Robert A Klug and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics. Which major investors are buying Quest Diagnostics stock? DGX stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of New York Mellon Corp, Bank of New York Mellon Corp, American Century Companies Inc., Tavio Capital LLC, Montag & Caldwell LLC, Millennium Management LLC and Teacher Retirement System of Texas. View Insider Buying and Selling for Quest Diagnostics. How do I buy shares of Quest Diagnostics? Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Quest Diagnostics' stock price today? One share of DGX stock can currently be purchased for approximately $108.08. How big of a company is Quest Diagnostics? Quest Diagnostics has a market capitalization of $14.65 billion and generates $7.71 billion in revenue each year. The medical research company earns $772 million in net income (profit) each year or $5.40 on an earnings per share basis. Quest Diagnostics employs 45,000 workers across the globe. How can I contact Quest Diagnostics? Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected] MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)Community Ranking: 1.8 out of 5 ()Outperform Votes: 347 (Vote Outperform)Underperform Votes: 629 (Vote Underperform)Total Votes: 976MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: What is the NASDAQ Stock Market?